EGFR and non-small cell lung carcinoma: In January 2023, mobocertinib was approved for marketing by the China National Drug Administration (NMPA) for treating patients with locally advanced or metastatic NSCLC that progressed during or after platinum-containing chemotherapy and had an EGFR ex20ins mutations.